Table 1: The Clinical Characteristic of the Patients Included in the Study
|
Etanercept Group (39 pts) |
Adalimumab Group (29 pts) |
Infliximab Group (21 pts) |
|
Age mean years |
59.6±9.8 |
58.7±10.6 |
60.1±9.3 |
|
Disease mean |
8.4±3.2 |
8.2±4.2 |
8.5±4.1 |
|
Female/Male |
33/6 |
25/4 |
19/2 |
|
Corticosteroid dose mg |
5.2±2.1 |
4.8±2.2 |
4.9±2.2 |
|
Methotrexate dose mg/w |
11.5±3.6 |
12.6±2.5 |
12.7±2.3 |
| RF
positive |
67% |
68% |
66% |
| Anti CC-P
positive |
83% |
81% |
80% |
|
DAS28 |
4.8±1.4 |
4.7±1.6 |
4.6±1.5 |
|
ESR mm/h |
49.3±12.5 |
51.2±9.6 |
51.6±9.9 |
|
CRP mg/dl |
3.2±1.4 |
3.3±1.6 |
3.1±1.8 |